Context Therapeutics Inc.
Context Therapeutics is dedicated to developing innovative therapies for solid tumors, focusing on next-generation T cell engaging bispecific antibody therapies. Their mission is to advance treatments that target specific tumor markers with high safety and efficacy, aiming to improve outcomes for patients with difficult-to-treat cancers.
Industries
Nr. of Employees
small (1-50)
Context Therapeutics Inc.
2001 Market Street, Suite 3915, Unit 15, Philadelphia, PA 19103
Patents
Products
Claudin-6 × CD3 bispecific antibody (clinical-stage)
A clinical-stage T cell-engaging bispecific antibody engineered to selectively bind Claudin-6 on tumor cells and CD3 on T cells to induce tumor cell lysis.
Mesothelin × CD3 bispecific antibody (clinical-stage)
A clinical-stage T cell-engaging bispecific antibody targeting mesothelin on tumor cells and CD3 on T cells for redirected T-cell cytotoxicity.
Nectin-4 × CD3 bispecific antibody (preclinical/clinical-stage)
A T cell-engaging bispecific antibody candidate targeting Nectin-4 on tumor cells and CD3 on T cells to mediate tumor cell killing.
Oral progesterone receptor antagonist (extended-release) — investigational
An orally administered progesterone receptor antagonist in an extended-release formulation developed to target PR-driven tumors, evaluated alone and in combination with endocrine therapies.
Claudin-6 × CD3 bispecific antibody (clinical-stage)
A clinical-stage T cell-engaging bispecific antibody engineered to selectively bind Claudin-6 on tumor cells and CD3 on T cells to induce tumor cell lysis.
Mesothelin × CD3 bispecific antibody (clinical-stage)
A clinical-stage T cell-engaging bispecific antibody targeting mesothelin on tumor cells and CD3 on T cells for redirected T-cell cytotoxicity.
Nectin-4 × CD3 bispecific antibody (preclinical/clinical-stage)
A T cell-engaging bispecific antibody candidate targeting Nectin-4 on tumor cells and CD3 on T cells to mediate tumor cell killing.
Oral progesterone receptor antagonist (extended-release) — investigational
An orally administered progesterone receptor antagonist in an extended-release formulation developed to target PR-driven tumors, evaluated alone and in combination with endocrine therapies.
Services
Granting of funds and contractual support for investigator-sponsored clinical trials that align with the company's therapeutic focus and meet specified scientific and regulatory criteria.
Policy-driven intake and review process for physician requests seeking access to investigational therapies outside of clinical trials, including timelines for acknowledgement and decision.
Design and execution of early-stage oncology clinical trials, including multicenter trial coordination, patient safety monitoring, and patient resources for trial participation.
Granting of funds and contractual support for investigator-sponsored clinical trials that align with the company's therapeutic focus and meet specified scientific and regulatory criteria.
Policy-driven intake and review process for physician requests seeking access to investigational therapies outside of clinical trials, including timelines for acknowledgement and decision.
Design and execution of early-stage oncology clinical trials, including multicenter trial coordination, patient safety monitoring, and patient resources for trial participation.
Expertise Areas
- Clinical trial management (Phase 1/2)
- T-cell engager bispecific antibody development
- CMC and biologics process development
- Preclinical efficacy and toxicology
Key Technologies
- T cell-engaging bispecific antibodies
- Membrane-protein-targeted antibody discovery
- In vitro cytotoxicity and cytokine assays
- Xenograft (in vivo) efficacy models
News & Updates
A Phase 1, First-in-Human Study of CTIM-76 in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors.
Preclinical studies and dose determination for CTIM-76, a Claudin-6 targeted bispecific antibody.
Research on onapristone as an anti-proliferative agent in breast cancer models.
A Phase 2 trial evaluating the efficacy of onapristone extended release in combination with other therapies for metastatic breast cancer.
Development and preclinical evaluation of a Claudin 6 bispecific antibody for ovarian cancer.
A Phase 1, First-in-Human Study of CTIM-76 in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors.
Preclinical studies and dose determination for CTIM-76, a Claudin-6 targeted bispecific antibody.
Research on onapristone as an anti-proliferative agent in breast cancer models.
A Phase 2 trial evaluating the efficacy of onapristone extended release in combination with other therapies for metastatic breast cancer.
Development and preclinical evaluation of a Claudin 6 bispecific antibody for ovarian cancer.